Influx Expands Its Dose: Thane Facility Set to Power Up Tablet Granulation Lines

Image Source: LinkedIn

Influx Healthtech Ltd, India's new industry leader in contract manufacturing, is scaling up its pharmaceutical manufacturing capacity through a scheduled expansion of its tablet granulation lines. The company has ensured its manufacturing at the recently refurbished manufacturing unit in Thane will be up and running in the coming months, ushering in a new era of expansion in its pharmaceutical and nutraceutical business.

Key Points:

The Thane plant expansion consists of the addition of tablet granulation lines that are state-of-the-art in order to improve the ability to produce dietary supplements and finished dosages.

The transaction forms a component of Influx's overall capital investment budget, which involves investments in veterinary and homecare product manufacturing plants.

The new factory is geared towards mass production of tablets, capsules, and oral powders for both domestic and foreign markets.

Strategic Context:

Influx Healthtech has recorded top-line growth to Rs 99.96 crore in FY24 from Rs 76.05 crore in FY23 while PAT rose to Rs 11.22 crore.

Company product line varies from nutraceuticals, cosmetics, ayurvedic products, and veterinary feed supplements.

With FDA and ISO certification, the Thane plant is poised to meet high standards of global quality levels.

Market Outlook:

The expansion is consistent with increasing demand for contract manufacturing in India's preventive healthcare and wellness markets.

Influx aims to use its higher profile to secure new B2B clients and boost exports on four continents.

Sources: BioVoice News, Influx Healthtech official website, Economic Times, Moneycontrol, Reuters